FDA eyes 1st schizophrenia drug in decades
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
FDA approves 1st new drug to treat schizophrenia in more than 30 years
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with schizophrenia.
FDA approves schizophrenia drug that could alter how disorder is treated
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of a brain chemical called acetylcholine.
First Novel Schizophrenia Treatment in Decades Gains FDA Approval
Cobenfy gives patients an alternative to drugs with troublesome side effects.
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
Revolutionary drug for schizophrenia wins US approval
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.
FDA eyes first schizophrenia drug shift in decades
The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least three decades. Why it matters: The complex condition is currently treated with antipsychotics that carry safety risks like metabolic disorders,
The FDA is expected to approve a new type of schizophrenia drug
The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
The FDA approves a new type of schizophrenia drug
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
FDA eyes 1st schizophrenia drug in decades: 5 things to know
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades,
FDA Lifts Clinical Hold On BMF-219
FDA’s views on AI are evolving
The guidance is based in part on responses the agency received to a 2023 discussion paper on the topic. The paper received ...
Scones Recall Update As FDA Sets Risk Level
Batches of Blueberry and Marionberry Scones have been recalled because of undeclared soy lecithin and soybean oil on the ...
STAT16h
FDA introduces plan to assess safety of common chemicals added to food
After years of pressure, the FDA said it is strengthening its review of many chemical additives used to enhance color, ...
studyfinds20h
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
FDA Warns Recalled Dog Food Should Be 'Thrown Out or Destroyed'
The pet food was found to be contaminated with bacteria that can cause illness and even death in pets and humans.
JD Supra16h
FDA to Study Presence of Metals in Tampons: What to Know
Biocompatibility and Toxicology Program published a statement announcing its intention to commission an independent literature review and internal bench laboratory study to evaluate the presence of ...
FDA Recalls Popular Milk Alternative in 27 States
Lactaid milk is being recalled in 27 states due to trace amounts of almonds, a popular allergen, potentially being present.
Hosted on MSN1d
Psilocybin vs Lexapro; FDA's KarXT Decision Nears; Obesity and Schizophrenia
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...